STRUCTURAL HEART
CoreValve Evolut-R TAVR (29mm) via Percutaneous Femoral Access – Aug 2016

A 79 year-old female presented with worsening dyspnea on exertion– NYHA class III and fatigue, with a history of hypertension, HPL, left breast CA, obesity, non-ischemic CM, non-obstructive CAD, gastric bypass (1983), left mastectomy with reconstruction (1985) and AICD (2010). TTE revealed Severe valvular aortic stenosis; peak gradient = 64 mmHg, mean gradient = 44 mmHg, Doppler valve area = 0.63 sq cm, Ao peak CW velocity = 4 m/sec, LVEF 33 %. CT angio showed minimum diameters of >6 mm for bilateral common femoral arteries and aortic annulus of 2.6 X 2.2 cm (average 2.45 cm). The STS risk mortality is 3.0 % and the Logistic Euroscore mortality is 6.7%. Patient was determined to be high risk for surgical AVR due to history of breast CA (post radiation therapy) and non-ischemic cardiomyopathy. Patient is now planned for Evolut-R CoreValve TAVR (29 mm) via percutaneous femoral access under conscious sedation.

45:58

comments

Leave Your Comments

suggestion
Suggestions
Valve-in-Valve TAVR with 26mm SAPIEN-3 – March 2019
Views247

79 year old man presents with worsening exertional dyspnea (NYHA Class III) for the last 3 months. Patient has required […]


50:31
Valve-in-Valve TAVR with 29mm Evolut-R CoreValve – January 2019
Views467

79 year old man presents with progressive exertional dyspnea (NYHA Class III) for the last 2 months.


1:07:06
TAVR 29mm Sapien-3 – November 2018
Tags:
Views670

96 year old male presents with progressive exertional dyspnea (NYHA Class III) for the last 4 months.


49:42
TAVR in a Patient with Prior Mitral Valve Replacement – September 2018
Tags: |
Views649

87 year old female presents with progressive exertional dyspnea (NYHA Class III) for the last 3 months.